HASBROUCK HEIGHTS, N.J., Oct. 19, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the podium presentation of new data on the long term safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) at the Annual Meeting of the North Central Section of the American Urological Association in Rancho Mirage, CA on October 19, 2011. Neal Shore MD FACS, the Medical Director of the Carolina Urologic Research Center and a highly experienced clinical trial investigator, reviewed the progress of the clinical trial program for NX-1207 to date and presented new analyses of long-term follow-up data for up to 6 ½ years after a single treatment with NX-1207.
